T-DM1 in persistent HER2+ disease after neoadjuvant chemo + surgery2. Keynote-905: Neoadjuvant Enfortumab Vedotin + pembro in cisplatin-ineligible bladder cancer3. POTOMAC: Durvalumab + BCG in non-muscle invasive bladder cancer4. IMvigor011: ctDNA-guided adjuvant atezolizumab in bladder cancer5. Dynamic-III: ctDNA guide de-escalation or escalation of chemotherapy in stage III colon cancer6. HARMONi-6: an excuse to talk about ivonescimab, a bispecific antibody unlike any other currently FDA approved